FDA and FTC warned BGP, LLC that its Biocence topical antiseptic is an unapproved, misbranded drug sold with COVID-19 treatment and prevention claims.
What happened
FDA and FTC reviewed www.biocence.com on February 9, 2021 and May 11, 2021, along with linked Facebook and Instagram pages. The agencies found the product labeled and promoted as an OTC drug with claims that it prevents or treats COVID-19 and other diseases, and with statements suggesting FDA approval. FDA says the product is an unapproved new drug and is misbranded.
What FDA found
The product is a new drug sold without an FDA-approved application.
section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)The labeling is false or misleading because it says the product is FDA approved or registered.
section 502(a) of the FD&C Act, 21 U.S.C. § 352(a)The product does not meet the conditions for marketing without approval under section 505G.
section 502(ee) of the FD&C Act, 21 U.S.C. § 352(ee)The active ingredient, Biocence Botanical Complex, was not a proposed active ingredient in the topical antiseptic rulemaking.
section 505G(a)(3) of the FD&C Act, 21 U.S.C. § 355h(a)(3)The label claims benefits beyond a topical antiseptic, such as killing COVID-19, MRSA, H1N1, Ebola, and HIV and treating wounds.
1994 TFM, as amended by the 2015 and 2016 proposed rulesThe company advertised that the product can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. 41 et seq.
What FDA wants
FDA tells BGP to take immediate action to stop selling the unapproved and misbranded COVID-19 products and to email COVID-19-Task-Force-CDER@fda.hhs.gov within 48 hours with the steps taken, documents, and a plan to prevent recurrence. FTC separately asks for an email to rcleland@ftc.gov within 48 hours describing corrective actions.
Who should pay attention
- consumers buying COVID-19 products online
- retailers and marketplaces listing OTC antiseptics
- companies making antiviral or antibacterial claims on websites and social media
This is a summary. Read the original letter on fda.gov.